Ventyx Biosciences, Inc.
VTYX
$1.20
-$0.06-4.76%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.42% | -0.34% | 8.05% | 21.92% | 26.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.63% | -15.21% | 9.48% | 55.87% | 83.84% |
| Operating Income | 28.63% | 15.21% | -9.48% | -55.87% | -83.84% |
| Income Before Tax | 29.97% | 15.93% | -8.52% | -54.55% | -77.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 29.97% | 15.93% | -8.52% | -54.55% | -77.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.97% | 15.93% | -8.52% | -54.55% | -77.97% |
| EBIT | 28.63% | 15.21% | -9.48% | -55.87% | -83.84% |
| EBITDA | 28.70% | 15.28% | -9.44% | -55.87% | -83.90% |
| EPS Basic | 39.59% | 24.22% | 0.34% | -42.23% | -60.40% |
| Normalized Basic EPS | 39.58% | 24.22% | 0.34% | -42.23% | -60.39% |
| EPS Diluted | 39.59% | 24.22% | 0.34% | -42.23% | -60.40% |
| Normalized Diluted EPS | 39.58% | 24.22% | 0.34% | -42.23% | -60.39% |
| Average Basic Shares Outstanding | 16.96% | 13.08% | 11.47% | 9.90% | 11.59% |
| Average Diluted Shares Outstanding | 16.96% | 13.08% | 11.47% | 9.90% | 11.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |